Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes

Journal of Nanjing Medical University

Volumn 23, Issue 4, 2009, Pages 228-235

  Wu, Jing ^a   Chen, Yiding ^a   Shi, Xiaoli ^a   Gu, Wei ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

dipeptidyl peptidase IV; DPP IV inhibitors; incretin hormone; type 2 diabetes

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ACARBOSE; ALOGLIPTIN; DENAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBORNURIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INCRETIN; INSULIN; ISOPHANE INSULIN; KRP 104; METFORMIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; MIGLITOL; NATEGLINIDE; PHX 1149; PHX 1149T; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SYR 619; UNCLASSIFIED DRUG; VILDAGLIPTIN; VOGLIBOSE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADD ON THERAPY; ANEMIA; CLINICAL TRIAL; DIARRHEA; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; EDEMA; FLATULENCE; GLYCEMIC CONTROL; HORMONE INHIBITION; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN SENSITIVITY; LACTIC ACIDOSIS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 71649111103     PISSN: 10074376     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1007-4376(09)60061-7     Document Type: Review

References (50)

1. Pratley R.E., and Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2diabetes. Curr Med Res Opin 23 (2007) 919-931
2. Bharatam P.V., Patel D.S., Adane L., Mittal A., and Sundriyal S. Modeling and informatics in designing anti-diabetic agents. Curr Pharm Des 13 (2007) 3518-3530
3. Geelhoed-Duijvestijn P.H. Incretins: a new treatment option for type 2 diabetes?. Neth J Med 65 (2007) 60-64
4. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60 (2006) 1454-1470
5. Matuszek B., Lenart-Lipińska M., and Nowakowski A. Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones(incretins) on glucose metabolism. Endokrynol Pol 58 (2007) 522-585
6. Hansotia T., and Drucker D.J. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 128 (2005) 125-134
7. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 21 (2007) 517-533
8. Yip R.G.C., and Wolfe M.M. GIP biology and fat metabolism. Life Sci 66 (2000) 91-103
9. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89 (1992) 8641-8645
10. Usdin T.B., Mezey E., Button D.C., Brownstein M.J., and Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133 (1993) 2861-2870
11. Langley A.K., Suffoletta T.J., and Jennings H.R. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 27 (2007) 1163-1180
12. MacDonald P.E., El-Kholy W., Riedel M.J., Salapatek A.M., Light P.E., and Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 (2002) S434-S442
13. Langley A.K., Suffoletta T.J., and Jennings H.R. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 27 (2007) 1163-1180
14. Fehmann H.C., Göke R., and Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucosedependent insulin releasing polypeptide. Endocr Rev 16 (1995) 390-410
15. Gautier J.F., Fetita S., Sobngwi E., and Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31 (2005) 233-242
16. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
17. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., and Holst J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38 (1993) 665-673
18. Deacon C.F., Nauck M.A., Meier J., Hücking K., and Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85 (2000) 3575-3581
19. Deacon C.F. Circulation and degradation of GIP and GLP-1. Hormone Metab Res 36 (2004) 761-765
20. Lambeir A.M., Durinx C., Scharpe S., and De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP-IV. Crit Rev Clin Lab Sci 40 (2003) 209-294
21. Abbott C.A., Baker E., Sutherland G.R., and McCaughan G.W. Genomic organization, exact localization, and tissue expression of the human CD26(dipeptidyl peptidase IV) gene. Immunogenetics 40 (1994) 331-338
22. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., Yoshikawa S., Asano O., et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 284 (2001) 501-506
23. Marguet D., Baggio L., Kobayashi T., Bernard A.M., and Pierres M. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97 (2000) 6874-6879
24. Reimer M.K., Holst J.J., and Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146 (2002) 717-727
25. Ahrén B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., and Jansson P.A. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
26. Pratley R.E., and Gilbert M. Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 5 (2008) 73-94
27. Pratley R.E. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 10 (2008) 171
28. Brandt I., Joossens J., and Xin C. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin((2S)-{[3-hydroxyadamantan-1-yl)acetyl}-pyrrolidine-2-carbonitrile. Biochem Pharmacol 70 (2005) 134-143
29. He Y.L., Sabo R., Campestrini J., and Wang Y. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 63 (2007) 677-686
30. Ahrén B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
31. Ristic S., Byiers S., Foley J., and Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin(LAF237) dose response. Diabetes Obes Metab 7 (2005) 692-698
32. Mari A., Sallas W.M., He Y.L., Watson C., and Ligueros-Saylan M. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 4888-4894
33. Matikainen N., Mänttäri S., Schweizer A., Ulvestad A., Ulvestad A., Mills D., Dunning B.E., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49 (2006) 2049-2057
34. Pratley R.E., Jauffret-Kamel S., Galbreath E., and Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38 (2006) 423-428
35. Pi-Sunyer F.X., Schweizer A., Mills D., and Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 76 (2007) 132-138
36. Scherbaum W.A., Schweizer A., Mari A., Nilsson P.M., Lalanne G., Jauffret S., et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 10 (2008) 675-682
37. Utzschneider K.M., Tong J., Montgomery B., Udayasankar J., and Gerchman F. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31 (2008) 108-113
38. Ahrén B., Gomis R., Standl E., Mills D., and Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2874-2880
39. Ahrén B., Pacini G., Foley J.E., and Schweizer A. Improved mealrelated beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28 (2005) 1936-1940
40. Bosi E., Camisasca R.P., Collober C., Rochotte E., and Garber A.J. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30 (2007) 890-895
41. He Y.L., Flannery B., Campestrini J., Leon S., Zinny M.A., Ligueros-Saylan M., et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 24 (2008) 1703-1709
42. Garber A.J., Schweizer A., Baron M.A., Rochotte E., and Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 9 (2007) 166-174
43. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., and Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 (2007) 1148-1155
44. Scott R., Wu M., Sanchez M., and Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61 (2007) 171-180
45. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
46. Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., and Amatruda J.M. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 24 (2008) 537-550
47. Rosenstock J., Brazg R., Andryuk P.J., Lu K., and Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 (2006) 1556-1568
48. Lauster C.D., McKaveney T.P., and Muench S.V. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm 64 (2007) 1265-1273
49. Choy M., and Lam S. Sitagliptin: a novel drug for the treatment of type 2 diabetes. Cardiol Rev 15 (2007) 264-271
50. Idris I., and Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 9 (2007) 153-165